课题基金 / 基金详情

Selective Editing of the Mutant Huntingtin Gene

Selective Editing of the Mutant Huntingtin Gene
突变亨廷顿基因的选择性编辑
批准号:
10381659
负责人:
NEIL ARONIN
金额:
$47.12万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-04-01 至 2024-03-31

项目摘要

项目成果

NEIL ARONIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The cause of Huntington’s disease is an increase in the trinucleotide CAG repeat from under 36 repeats to 36 or greater repeats. The mode for the number of repeats is 42, and most patients have between 40 and 45. The disease generally starts between ages 30 and 40, with onset and progression of impaired cognition, depression, and aberrant movement. The genetics is autosomal dominant. With gene editing, we aim to eliminate expression of the mutant allele of Huntington’s disease or repair the mutation by reducing the number of CAG repeats. We will use CRISPR-Cas9 for selective targeting of single nucleotide polymorphisms with heterozygosities to prevent the mutant huntingtin allele from producing protein. Generating frameshift mutations at the SNP heterozygosity reduces mutant huntingtin protein, with no production of mutant protein fragments. In a second approach, we reduce the number of CAG repeats from a high number in the mutant allele to a healthy number of CAG repeats, through the use of Cas9 nickases. The nickase Cas9D10A is used to reduce the CAG repeat number below the pathogenic threshold. We have preliminary data that supports each aspect of the proposal. The goal of this discovery application is to set the stage for promising therapeutics for treatment of Huntington’s disease and other autosomal dominant neurological disorders caused by trinucleotide CAG repeat expansions.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Advancing RNA Therapeutics for Huntington's Disease
Advancing RNA Therapeutics for Huntington’s Disease
Advancing RNA Therapeutics for Huntington’s Disease
Advancing RNA Therapeutics for Huntington’s Disease
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: